{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:06:31Z","timestamp":1779195991415,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Adolescent and Young Adult Oncology"],"published-print":{"date-parts":[[2017,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To estimate the risk\u2013benefit trade-off of a pediatric-inspired regimen versus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) for first-line treatment of adolescents\/young adult (AYA; ages 16\u201339 years) patients with Philadelphia-negative acute lymphoblastic leukemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patient outcomes were simulated using a 6-state Markov model, including complete response (CR), no CR, first relapse, second CR, second relapse, and death. A Weibull distribution was fit to the progression-free survival curve of hyper-CVAD\u2013treated AYA patients from a single-center study, and comparable patient data from a retrospective study of pediatric regimen\u2013treated AYA patients were utilized to estimate a relative progression difference (hazard ratio\u2009=\u20090.51) and model survival differences. Health-state utilities were estimated based on treatment stage, with an assumption that the pediatric protocol had 0.10 disutility compared with hyper-CVAD before the maintenance phase of treatment. Total life-years and quality-adjusted life-years (QALYs) were compared between treatment protocols at 1, 5, and 10 years, with additional probabilistic sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Treatment with the pediatric-inspired protocol was associated with a 0.04 increase in life-years, but a 0.01 decrease in QALYs at 1 year. By years 5 and 10, the pediatric-inspired protocol resulted in 0.18 and 0.24 increase in life-years and 0.25 and 0.32 increase in QALYs, respectively, relative to hyper-CVAD. The lower quality of life associated with the induction and intensification phases of pediatric treatment was offset by more favorable progression-free survival and overall survival relative to hyper-CVAD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our exploratory analysis suggests that, compared with hyper-CVAD, pediatric-inspired protocols may increase life-years throughout treatment stages and QALYs in the long term.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jayao.2016.0049","type":"journal-article","created":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T10:21:46Z","timestamp":1477390906000},"page":"53-61","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk\u2013Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults"],"prefix":"10.1177","volume":"6","author":[{"given":"Gregory F.","family":"Guzauskas","sequence":"first","affiliation":[{"name":"University of Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen F.","family":"Villa","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geertrui F.","family":"Vanhove","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki L.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Veenstra","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,10,25]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2010.0001"},{"key":"#cr-split#-e_1_3_3_3_2.1","unstructured":"Howlader N Noone A Krapcho M et al. SEER Cancer Statistics Review 1975-2010 based on November 2012 SEER data submission. Bethesda MD: National Cancer Institute"},{"key":"#cr-split#-e_1_3_3_3_2.2","unstructured":"2013. Accessed August25 2015 from: http:\/\/seer.cancer.gov\/archive\/csr\/1975_2010\/browse_csr.php?sectionSEL=13&pageSEL=sect_13_table.12.html"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11664"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05544.x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.596963"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.11.3995"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-051912"},{"issue":"6","key":"e_1_3_3_9_2","first-page":"957","article-title":"Incidence and clinical outcome of children with BCR\/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92","volume":"10","author":"Schlieben S","year":"1996","unstructured":"Schlieben S, , Borkhardt A, , Reinisch I, et al. Incidence and clinical outcome of children with BCR\/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia., 1996; 10(6):957\u201363.","journal-title":"Leukemia."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.3.489.489"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju300"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70192-1"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-130237"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0325"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23149"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.77"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2011.1511"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23060"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07712.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.26.3.684"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/jayao.2015.0014"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-014-0210-9"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.3903.3903"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24938"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.72"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/697675"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.053"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403538"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22189"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20749"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24419"},{"key":"e_1_3_3_35_2","unstructured":"National Comprehensive Cancer Network Inc. NCCN Clinical Practice Guidelines in Oncology: Acute Lymphoblastic Leukemia. Version 1.2016. Accessed September12 2016 from: www.nccn.org\/patients\/guidelines\/all\/#"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.796.796"}],"container-title":["Journal of Adolescent and Young Adult Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jayao.2016.0049","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jayao.2016.0049","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jayao.2016.0049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:08:33Z","timestamp":1779192513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jayao.2016.0049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3,1]]}},"alternative-id":["10.1089\/jayao.2016.0049"],"URL":"https:\/\/doi.org\/10.1089\/jayao.2016.0049","relation":{},"ISSN":["2156-5333","2156-535X"],"issn-type":[{"value":"2156-5333","type":"print"},{"value":"2156-535X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,25]]}}}